NCT02094833View on ClinicalTrials.gov

DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

November 30, 2016

Conditions
DiphtheriaTetanusPertussisHaemophilus Influenzae Type b InfectionPoliomyelitisHepatitis B
Interventions
BIOLOGICAL

DTaP-IPV-Hep B-PRP~T combined vaccine

0.5 mL, Intramuscular

BIOLOGICAL

DTaP-IPV//PRP~T and Hepatitis B vaccine

0.5 mL, Intramuscular

Trial Locations (16)

301 724

Daejeon

425 707

Gyeonggi-do

Unknown

Gyeonggi-do

Gyeongsangnam Do

Seoul

641 560

Gyeongsangnam Do

570 711

Jeollabuk Do

561 712

Jeonbuk

220 701

Kangwon Do

420 717

Kyunggi Do

120 752

Seoul

130 87

Seoul

137 701

Seoul

139 709

Seoul

158 710

Seoul

442 723

Suwon Gyeonggi Do

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02094833 - DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants | Biotech Hunter | Biotech Hunter